U.K. Cost Regulator May Reject Gilead’s Sovaldi Treatment

June 16, 2014 10:03 AM

10 0

The U.K.’s health cost regulator said it’s inclined to reject Gilead Sciences Inc. (GILD:US)’s $60,000 hepatitis C drug Sovaldi, and asked for more data before deciding whether the government should pay for the treatment.

Sovaldi lacks evidence for some patient groups, the National Institute for Health and Care Excellence said in an e-mailed statement today. The agency said it has asked Foster City, California-based Gilead for more information, including about Sovaldi’s cost-effectiveness in patients with and without...

Read more

To category page

Loading...